599 related articles for article (PubMed ID: 30468254)
21. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
22. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
Jebaraj BMC; Müller A; Dheenadayalan RP; Endres S; Roessner PM; Seyfried F; Walliser C; Wist M; Qi J; Tausch E; Mertens D; Fox JA; Debatin KM; Meyer LH; Taverna P; Seiffert M; Gierschik P; Stilgenbauer S
Blood; 2022 Feb; 139(6):859-875. PubMed ID: 34662393
[TBL] [Abstract][Full Text] [Related]
24. The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Xargay-Torrent S; López-Guerra M; Rosich L; Montraveta A; Roldán J; Rodríguez V; Villamor N; Aymerich M; Lagisetti C; Webb TR; López-Otín C; Campo E; Colomer D
Oncotarget; 2015 Sep; 6(26):22734-49. PubMed ID: 26068951
[TBL] [Abstract][Full Text] [Related]
25. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M
JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
[TBL] [Abstract][Full Text] [Related]
27. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
28. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.
Ren L; Campbell A; Fang H; Gautam S; Elavazhagan S; Fatehchand K; Mehta P; Stiff A; Reader BF; Mo X; Byrd JC; Carson WE; Butchar JP; Tridandapani S
J Biol Chem; 2016 Feb; 291(6):3043-52. PubMed ID: 26627823
[TBL] [Abstract][Full Text] [Related]
30. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.
Burger JA; Li KW; Keating MJ; Sivina M; Amer AM; Garg N; Ferrajoli A; Huang X; Kantarjian H; Wierda WG; O'Brien S; Hellerstein MK; Turner SM; Emson CL; Chen SS; Yan XJ; Wodarz D; Chiorazzi N
JCI Insight; 2017 Jan; 2(2):e89904. PubMed ID: 28138560
[No Abstract] [Full Text] [Related]
31. Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Javidi-Sharifi N; Brown JR
Expert Rev Hematol; 2024 Jun; 17(6):201-210. PubMed ID: 38784995
[TBL] [Abstract][Full Text] [Related]
32. Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.
Niemann CU; Mora-Jensen HI; Dadashian EL; Krantz F; Covey T; Chen SS; Chiorazzi N; Izumi R; Ulrich R; Lannutti BJ; Wiestner A; Herman SEM
Clin Cancer Res; 2017 Oct; 23(19):5814-5823. PubMed ID: 28645939
[No Abstract] [Full Text] [Related]
33. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
[TBL] [Abstract][Full Text] [Related]
34. BTK Inhibitors in Chronic Lymphocytic Leukemia.
Gaballa S; Pinilla-Ibarz J
Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
[TBL] [Abstract][Full Text] [Related]
35. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
36. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
[TBL] [Abstract][Full Text] [Related]
37. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
Rhodes JM; Mato AR
Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
[TBL] [Abstract][Full Text] [Related]
38. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
Glavey S; Quinn J; McCloy M; Sargent J; McCartney Y; Catherwood M; Marafioti T; Leader M; Murphy P; Thornton P
Eur J Haematol; 2017 Oct; 99(4):378-380. PubMed ID: 28561533
[TBL] [Abstract][Full Text] [Related]
39. Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE; Brown JR
Front Immunol; 2021; 12():687458. PubMed ID: 34248972
[TBL] [Abstract][Full Text] [Related]
40. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
